Erasca (ERAS) Gains from Investment Securities (2021 - 2025)
Erasca posted quarterly Gains from Investment Securities of $297000.0 for Q4 2025, down 24.81% year-on-year from $395000.0 in Q4 2024, and up 471.15% on a QoQ basis from $52000.0 in Q3 2025.
Erasca (ERAS) has 5 years of Gains from Investment Securities data on file, last reported at $297000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 24.81% year-over-year to $297000.0; the trailing twelve-month figure through Dec 2025 stood at $802000.0 (down 32.03% YoY), and the FY2025 full-year result was $47.5 million, up 39.96% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $297000.0, up from $52000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $47.2 million in Q1 2025 and bottomed at $52000.0 in Q3 2025.
- The 5-year median for Gains from Investment Securities is $395000.0 (2024), against an average of $6.1 million.
- The widest annual swing landed in 2024, when Gains from Investment Securities tumbled 99.55%; it then jumped 40472.8% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022, then slumped by 80.93% to $286000.0 in 2023, then jumped by 38.11% to $395000.0 in 2024, then retreated by 24.81% to $297000.0 in 2025.
- The last three Gains from Investment Securities figures came in at $297000.0 (Q4 2025), $52000.0 (Q3 2025), and $58000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 297,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Sep 30, 2025 | 52,000.00 |
| Sep 30, 2025 | 52,000.00 |
| Jun 30, 2025 | 58,000.00 |
| Jun 30, 2025 | 58,000.00 |
| Mar 31, 2025 | 47.25 Mn |
| Mar 31, 2025 | 47.25 Mn |
| Dec 31, 2024 | 395,000.00 |
| Dec 31, 2024 | 395,000.00 |
| Jun 30, 2024 | 123,000.00 |
| Jun 30, 2024 | 123,000.00 |
| Mar 31, 2024 | 116,449.00 |
| Mar 31, 2024 | 116,449.00 |
| Dec 31, 2023 | 286,000.00 |
| Dec 31, 2023 | 286,000.00 |
| Sep 30, 2023 | 11.61 Mn |
| Sep 30, 2023 | 11.61 Mn |
| Jun 30, 2023 | 376,000.00 |
| Jun 30, 2023 | 376,000.00 |
| Mar 31, 2023 | 25.89 Mn |
| Mar 31, 2023 | 25.89 Mn |
| Sep 30, 2022 | 1.50 Mn |
| Sep 30, 2022 | 1.50 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Jun 30, 2021 | 1.50 Mn |
| Jun 30, 2021 | 1.50 Mn |
| Mar 31, 2021 | 424,000.00 |
| Mar 31, 2021 | 424,000.00 |